Skip to main content
SpringerLink
Log in

Lymphoplasmozytisches Lymphom/Makroglobulinämie Waldenström

  • Chapter
Kompendium Internistische Onkologie

  • 142 Accesses

Zusammenfassung

Morphologische und immunhistochemische Kriterien führten innerhalb der Kiel-Klassifikation zur Differenzierung zwischen der chronischen lymphatischen Leukämie (BCLL) und dem Immunzytom (Lennert u. Feller 1992). Dabei werden ein lymphoplasmozytoides (REAL-Klassifikation: B-CLL mit lymphoplasmozytoider Differenzierung) und ein lymphoplasmozytisches Immunozytom (REAL-Klassifikation: lymphoplasmozytisches Lymphom/Immunozytom) unterschieden (Harris et al. 1994). In der neuen World Health Organization Classification of Tumours (WHO-Klassifikation) (Jaffe et al. 2001) werden die CD5-positiven lymphozytischen Lymphome (einschließlich CLL) und die CD5-negativen lymphoplasmozytischen Lymphome voneinander unterschieden. Für die klinische und prognostische Bedeutung dieser Unterteilung sprechen die Ergebnisse prospektiver, multizentrischer Beobachtungsstudien (Brittinger et al. 1984; Engelhard et al. 1991). Die WHO-Klassifikation definiert das lymphoplasmozytische Lymphom/Makroglobulinämie Waldenström als eine Neoplasie, die von kleinen Lymphozyten vom B-Zell-Typ, plasmozytoiden Lymphozyten und Plasmazellen gebildet wird, die in der Regel das CD5-Antigen nicht exprimieren (Jaffe et al. 1999). Dabei ist wichtig, daß die Sekretion von IgM nicht auf die Makroglobulinämie Waldenström beschränkt ist, sondern mit verschiedenen Lymphomen assoziiert sein kann. Diese plasmozytoiden oder -zytischen Varianten anderer Lymphome werden jetzt im Unterschied zur früheren Definition des Immunozytoms der Kiel-Klassifikation (lymphoplasmozytoider Subtyp) ausgeschlossen und den entsprechenden Lymphomentitäten als lymphoplasmozytoide Varianten zugeordnet (Jaffe et al. 2001).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Anagnostopoulos A, Giralt S (2002) Stem cell transplantation (SCT) for Waldenstrom’s macroglobulinemia (WM). Bone Marrow Transplant 29:943–947

    Article  PubMed  CAS  Google Scholar 

  • Anonymos (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 319:902–907

    Article  Google Scholar 

  • Bagley CM, Jr., Devita VT, Jr., Berard CW, Canellos GP (1972) Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76:227–234

    PubMed  Google Scholar 

  • Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356

    PubMed  CAS  Google Scholar 

  • Berger F, Isaacson PG, Piris MA et al (2001) Lymphoplasmocytic lymphoma/Waldenström macroglobulinemia. In: World Health Organization Classificaflon of Tumours-Pathology Tumours of Hematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC) edn. IARC Press, Lyon, pp 132–134

    Google Scholar 

  • Binet J (1981) Chronic lymphocytic leukaemia: proposals for a revised prognostic staging system. Report from the International Workshop on CLL. Br J Haematol 48:365–367

    Article  Google Scholar 

  • Brittinger G, Bartels H, Common H et al (1984) Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2:269–306

    PubMed  CAS  Google Scholar 

  • Byrd JC, White CA, Link B et al (1999) Rituximab therapy in Waldenstrom’s macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 10:1525–1527

    Article  PubMed  CAS  Google Scholar 

  • Carbone PP, Kaplan HS, Musshoff K et al (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31:1860–1861

    PubMed  CAS  Google Scholar 

  • Chabner BA, Bates SE, Fojo AT et al (1994) Drug resistance in adult lymphomas. Semin Hematol 31:70–87

    PubMed  CAS  Google Scholar 

  • Cheson BD (2002) Hematologic malignancies new developments and future treatments. Semin Oncol 29:33–45

    Article  PubMed  Google Scholar 

  • Cheson BD, Bennett JM, Rai KR et al (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 29:152–163

    Article  PubMed  CAS  Google Scholar 

  • Clavio M, Quintino S, Venturino C et al (2001) Lymphoplasmocytic lymphoma/immunocytoma: towards a disease-targeted treatment? J Exp Clin Cancer Res 20:351–358

    PubMed  CAS  Google Scholar 

  • Dhodapkar MV, Jacobson JL, Gertz MA et al. (2001) Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 98:41–48

    Article  PubMed  CAS  Google Scholar 

  • Dimopoulos MA, Kantarjian H, Weber D et al (1994) Primary therapy of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694–2698

    PubMed  CAS  Google Scholar 

  • Dimopoulos MA, Panayiotidis P, Moulopoulos LA et al (2000) Waldenstrom’s macroglobulinemia: clinical features, complications, and management. J Clin Oncol 18:214–226

    PubMed  CAS  Google Scholar 

  • Dimopoulos MA, Zervas C, Zomas A et al (2002) Treatment of Waldenstrom’s macroglobulinemia with rituximab. J Clin Oncol 20:2327–2333

    Article  PubMed  CAS  Google Scholar 

  • Engelhard M, Brittinger G, Heinz R et al (199l) Chronic lymphocytic leukaemia (BCLL) and immunocytoma (LP-IC): Clinical and prognostic relevance of this distinction. Leuk Lymphoma (Suppl):161–173

    Google Scholar 

  • Epelbaum R, Kuten A, Coachman NM et al (1992) Stage I-II low grade non-Hodgkin’s lymphoma: prognostic factors and treatment results. Strahlenther Onkol 168:66–72

    PubMed  CAS  Google Scholar 

  • Foran JM, Oscier D, Orchard J et al (1999) Pharmacokinetlc study of single doses of oral fludarabine phosphate in patients with “low-grade” non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 17:1574–1579

    PubMed  CAS  Google Scholar 

  • Foran JM, Rohatiner AZ, Cunningham D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monodonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317–324

    PubMed  CAS  Google Scholar 

  • French Cooperative Group on Chronic Lymphocytic Leukaemia (1986) Effectiveness of “CHOP” regimes in advanced untreated chronic lymphocytic leukaemia. Lancet 1:1346–1349

    Google Scholar 

  • Garcia-Sanz R, Montoto S, Torrequebrada A et al (2001) Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 115:575–582

    Article  PubMed  CAS  Google Scholar 

  • Gertz MA, Anagnostopoulos A, Anderson K et al (2003) Treatment recommendations in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2):121–126

    Article  PubMed  Google Scholar 

  • Grossbard ML, Press OW, Appelbaum FR et al (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863–878

    PubMed  CAS  Google Scholar 

  • Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    PubMed  CAS  Google Scholar 

  • Jaffe ES, Campo E, Raffeld M (1999) Mantle cell lymphoma. Hematology (ASH Education Program Book) 319–324

    Google Scholar 

  • Jaffe ES, Harris NL, Stein H, Vardiman J (2001) Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. IARC Press

    Google Scholar 

  • Kempin S, Lee BJ III, Thaler HT et al (1982) Combination chemotherapy of advanced chronic lymphocytic leukemia: the M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 60:1110–1121

    PubMed  CAS  Google Scholar 

  • Klasa RJ (2001) Rational approaches to design of therapeutics targeting molecular markers. Hematology-ASH Education Program Book 1:443–471

    Google Scholar 

  • Knospe WH, Loeb V, Jr., Huguley CM, Jr. (1974) Proceedings: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 33:555–562

    Article  PubMed  CAS  Google Scholar 

  • Kyle RA, Treon SP, Alexanian R et al (2003) Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendation from the Second International Workshop on Waldenstrom’s Macroglobulinemia. In: Treon SP (ed) Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2):116–120

    Google Scholar 

  • Lawrence TS, Urba WJ, Steinberg SM et al (1988) Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 14:417–424

    PubMed  CAS  Google Scholar 

  • Leblond V, Ben Othman T, Deconinck E et al (1998) Activity of fludarabine in previously treated Waldenstrom’s macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J Clin Oncol 16:2060–2064

    PubMed  CAS  Google Scholar 

  • Lennert K, Feller AC (1992) Histopathology of non-Hodgkin’s lymphoma. (Based on the updated Kiel classification). Springer Verlag

    Google Scholar 

  • Levy V, Porcher R, Leblond V et al (2001) Evaluating treatment strategies in advanced Waldenstrom macroglobulinemia: use of quality-adjusted survival analysis. Leukemia 15:1466–1470

    Article  PubMed  CAS  Google Scholar 

  • Montserrat E, Alcala A, Parody R et al (1985) Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer 56:2369–2375

    Article  PubMed  CAS  Google Scholar 

  • Musshoff K, Schmidt-Vollmer H (1975) Proceedings: Prognosis of non-Hodgkin’s lymphomas with special emphasis on the staging classification. Z Krebsforsch 83:323–341

    Article  CAS  Google Scholar 

  • Owen RG, Treon SP, Al-Katib A et al (2003) Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. In: Treon SP (ed) Waldenstrom’s Macroglobulinemia. Semin Oncol 30(2): 110–115

    Google Scholar 

  • Papamichael D, Norton AJ, Foran JM et al (1999) Immunocytoma: a retrospective analysis from St Bartholomew’s Hospital — 1972 to 1996. J Clin Oncol 17:2847–2853

    PubMed  CAS  Google Scholar 

  • Rai KR, Rabinowe SN (1993) Cancer Medicine, 3rd ed. Lea 234

    Google Scholar 

  • Sack H, Budach V, Stuschke M, Hoederath A (1992) Non-Hodgkin lymphomas (NHL) — early stages: interim results of a multicentre trial. Cancer Res Clin Oncol 16: Abstract V6.10.07 (R115)

    Google Scholar 

  • Sawitzky A, Rai KR, Glidewell O, Silver RT (1977) Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50:1049–1059

    Google Scholar 

  • Taylor RE, Allan SG, McIntyre MA et al (1988) Low grade stage I and II non-Hodgkin’s lymphoma: results of treatment and relapse pattern following therapy Clin Radiol 39:287–290

    PubMed  CAS  Google Scholar 

  • Wagner SD, Martinelli V, Luzzatto L (1994) Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom’s macroglobulinemia, and myeloma. Blood 83:3647–3653

    PubMed  CAS  Google Scholar 

  • Yahalom J (1999) Radiation therapy in the treatment of lymphoma. Curr Opin Oncoly pp. 370–374

    Google Scholar 

  • Yahalom J, Varsos G, Fuks Z (1993) Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71:2342–2350

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Meusers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. U. Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Engelhard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Hallek, M., Meusers, P., Jäger, U., Engelhard, M. (2006). Lymphoplasmozytisches Lymphom/Makroglobulinämie Waldenström. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_176

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_176

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation